RE:RE:RE:RE:RE:52 Weeks low???As long as sales and net revenue remain high enough continue servicing their debt payments then they are fine going forward. If they keep their expenses down and revenues are high enough then they will be able to start banking money for the 2023 debentures. Any monies raised through the sale of the unneeded components of Zenabis and 48 North will contribute to their cash position.
In all honestly we are likely not going to get a chance to accurately project those numbers out to 2023 until we see the Dec 15th report with the first real view of the new sales on it. The March 2022 report will provide more clarity as well as we will start seeing sales figures coming in from their expansion to the 17 US States.
Getting back to the 2023 debentures, if the CEO states that they will address all (or most of) any cash gap through traditional financing then I think that will go over well in the market. If they have... oh I don't know... maybe a Fortune 200 Company sitting in the wings with a supply agreement pending then that will also be a huge incremental source of net revenue.
JMHO
Q
- Long on HEXO